Response: Commentary: An In Silico–In Vitro Pipeline Identifying an 
HLA-A*02:01+ KRAS G12V+ Spliced Epitope Candidate for a Broad Tumor-Immune 
Response in Cancer Patients

Mishto, M.; Rodriguez-Hernandez, G.; Neefjes, J.; Urlaub, H.; Liepe, J.

doi:10.3389/fimmu.2021.679836

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Response: Commentary: An In Silico–In Vitro Pipeline Identifying an HLA-A*02:01+ KRAS G12V+ Spliced Epitope Candidate for a Broad Tumor-Immune Response in Cancer Patients

MPS-Authors

/persons/resource/persons15947

Urlaub, H.
Research Group of Bioanalytical Mass Spectrometry, MPI for Biophysical Chemistry, Max Planck Society;

/persons/resource/persons208298

Liepe, J.
Research Group of Quantitative and System Biology, MPI for Biophysical Chemistry, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

3398348.pdf
(Publisher version), 5MB

Supplementary Material (public)

There is no public supplementary material available

Citation

Mishto, M., Rodriguez-Hernandez, G., Neefjes, J., Urlaub, H., & Liepe, J. (2021). Response: Commentary: An In Silico–In Vitro Pipeline Identifying an HLA-A*02:01+ KRAS G12V+ Spliced Epitope Candidate for a Broad Tumor-Immune Response in Cancer Patients. Frontiers in immunology, 12: 679836. doi:10.3389/fimmu.2021.679836.

Cite as: https://hdl.handle.net/21.11116/0000-000A-D2A4-F

Abstract

There is no abstract available